Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women
Open Access
- 1 February 2002
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 17 (2) , 341-348
- https://doi.org/10.1359/jbmr.2002.17.2.341
Abstract
Raloxifene is a selective estrogen receptor modulator that has been shown to increase bone density. The purpose of this study was to examine the effects of raloxifene on bone tissue by studying bone biopsy specimens before and after 2 years of raloxifene or placebo therapy. The women in this study were participants of the double‐blind, placebo‐controlled, multicenter study, the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Subjects from two U.S. sites and two European sites were included if they consented to a bone biopsy. Iliac crest bone biopsies were performed at baseline and after 2 years. Tetracycline labeling preceded each biopsy. A total of 65 paired biopsy specimens were evaluated with 25, 22, and 18 patients in the placebo, raloxifene HCl (60 mg) and raloxifene HCl (120 mg) treatment groups, respectively. They were analyzed using standard histomorphometry. None of the biopsy specimens showed evidence of toxic effects on bone or bone cells or met criteria for osteomalacia. Biopsy specimens in the placebo and raloxifene groups had the appearance of normal bone, with no evidence of marrow fibrosis or increases in the amount of woven bone or numbers of empty osteocyte lacunae. Compared with the baseline, the bone formation rate (BFR) decreased significantly in both raloxifene groups. The change in BFR in the group treated with 120 mg of raloxifene was −62.3%, which was significantly lower than the change in the placebo group of −21.0% (p = 0.03). No change in resorption parameters could be measured by histomorphometry, but there was a decrease in urinary type I collagen excretion. The results from this study suggest that raloxifene has actions on bone tissue that are similar to those observed with estrogen. The depressive effects on bone remodeling are less marked than the effects seen with alendronate.Keywords
This publication has 29 references indexed in Scilit:
- Bone Structure in Patients with Low Bone Mineral Density With or Without Vertebral FracturesJournal of Bone and Mineral Research, 2000
- Effects of Alendronate on Bone Quality and Remodeling in Glucocorticoid-Induced Osteoporosis: A Histomorphometric Analysis of Transiliac BiopsiesJournal of Bone and Mineral Research, 2000
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Effects of Ethnicity and Age or Menopause on Osteoblast Function, Bone Mineralization, and Osteoid Accumulation in Iliac BoneJournal of Bone and Mineral Research, 1997
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancerJournal of Bone and Mineral Research, 1994
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987
- Metabolic bone disease with and without osteomalacia after intestinal bypass surgery: A bone histomorphometric studyBone, 1985
- Histomorphometric analysis of dynamic parameters of trabecular bone formation in the iliac crest of Normal British subjectsMetabolic Bone Disease and Related Research, 1983
- The Jackknife Estimate of VarianceThe Annals of Statistics, 1981